Development of molecular target therapy using new angiogenin inhibitor against cancer induced bone diseases
Project/Area Number |
23390463
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Surgical dentistry
|
Research Institution | Okayama University |
Principal Investigator |
SASAKI AKIRA 岡山大学, 医歯(薬)学総合研究科, 教授 (00170663)
|
Co-Investigator(Kenkyū-buntansha) |
SHIMO Tsuyoshi 岡山大学, 大学院・医歯薬学総合研究科, 准教授 (40362991)
KISHIMOTO Koji 岡山大学, 大学院・医歯薬学総合研究科, 助教 (40243480)
IBARAGI Souitiro 岡山大学病院, 助教 (80549866)
YOSHIOKA Norie 岡山大学, 大学院・医歯薬学総合研究科, 助教 (50362984)
|
Project Period (FY) |
2011-04-01 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥12,870,000 (Direct Cost: ¥9,900,000、Indirect Cost: ¥2,970,000)
Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2012: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2011: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
Keywords | angiogenin / neomycine / 口腔扁平上皮癌 / 骨浸潤 / 癌誘発骨破壊 / 血管新生因子 / 破骨細胞 / 血管新生阻害薬 / angionenin / 骨破壊モデル / ノックアウトマウス / 骨破壊 / 癌 / 骨吸収 |
Research Abstract |
Osteoclast-mediated bone resorption plays an important role in bone invasion or bone destruction of the cancer. We have been establishing the treatment of the cancer induced-bone diseases which assumed angiogenesis factor, angiogenin (ANG) as a molecular target. In the present study, we examined a therapeutic utility of ANG inhibitor and investigated the role of ANG using ANG-1 knockout mouse (ANG-KO). Trabecular bone formation of the early period of growth was suppressed in ANG-KO compare to the wild type mice (WT), and the in vitro osteoclasts formation using cells of ANG-KO was inhibited, but there were few differences in vivo model. The ANG inhibitor was able to confirm a utility for a mouse cancer bone destruction model. Newly developed medicine, Terrein, which inhibit the production of ANG, had not only the inhibition of angiogenesis, but also the antitumor activity. Therefore, a utility of ANG inhibitors against the cancer induced bone diseases was suggested.
|
Report
(4 results)
Research Products
(5 results)